ALK inhibitors and advanced non-small cell lung cancer (review).

摘要: Abstract Treatment of unselected patients with advanced non-small cell lung cancer (NSCLC) receiving third-generation platinum-based chemotherapy has reached a plateau effectiveness. Histology and molecular analyses are the cornerstone in initial diagnosis NSCLC key determinants to address appropriate strategy treatment. In non-squamous histology combination cisplatin plus pemetrexed or carboplatin paclitaxel bevacizumab considered today best regimens yielding better activity efficacy. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), such as gefitinib, erlotinib afatinib standard-of-care for harbouring activating EGFR mutations. The identification anaplastic lymphoma (ALK) rearrangements 2-5% led rapid clinical development its oral TKI, crizotinib, also targeting proto-oncogene MET ROS1. results reported from first phase III trial showed superiority crizotinib compared standard second-line treatment ALK-positive NSCLC, which was recently approved several countries this setting. Unfortunately, after will ultimately develop acquired resistances within 1 2 years therapy. A second generation ALK inhibitors, LDK378, alectinib AP26113 may represent promising approach: they under investigation very early results. This review discusses rearrangements, use other ALK-TKIs NSCLC.